00:48 , Aug 2, 2019 |  BC Extra  |  Clinical News

Amicus’ Batten disease gene therapy shows preserved speech, motor function

Interim data for Amicus’ most advanced Batten disease gene therapy suggest that the biotech’s recent addition of the modality to its pipeline could be paying off. On Thursday, Amicus reported interim Phase I/II data showing...
18:09 , Dec 5, 2018 |  BC Innovations  |  Translation in Brief

Engaging with exosomes

A University of Southern California team has developed synthetic exosomes that express multiple multivalent antibodies, giving them a function like T cell bispecific antibodies, but potentially higher avidity. In a paper published in November in...
16:17 , Oct 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Zika virus Mouse studies suggest a vaccine based on Zika NS1, Env and prM could help prevent Zika infection. The vaccine consists of the three viral genes encoded in an attenuated recombinant vesicular stomatitis...
18:07 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Novo's REPAIR fund makes first investment in Swiss antibiotic company

Novo Holdings A/S invested CHF6.8 million ($7 million) on Sept. 6 into antibiotic company Polyphor Ltd. (SIX:POLN) through the purchase of 178,947 new shares at CHF38. The funds come from Novo's REPAIR Impact Fund, which...
22:51 , Jun 28, 2018 |  BC Innovations  |  Translation in Brief

Conformist nanobodies

A University of Zurich team in collaboration with Roche has figured out how to make fully synthetic nanobodies that can bind to membrane proteins in specific conformations -- simultaneously opening up new target space for...
17:46 , Jun 28, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; chemistry; drug platforms

TECHNOLOGY: Binding assays; tool compounds; antibody scaffolds A method for generating and screening synthetic nanobodies could be used to identify compounds that bind membrane proteins in a conformation-specific manner, for use as therapeutics or research...
19:07 , May 4, 2018 |  BC Week In Review  |  Financial News

A-Mansia raises €16M for the microbiome

A-Mansia Biotech S.A. (Louvain-la-Neuve, Belgium) raised €13 million ($16 million) in the first close of a tranched series A round led by Seventure Partners with participation from Fonds Vives II, the SRIW Life Sciences, Nivelinvest...
14:30 , Apr 27, 2018 |  BC Extra  |  Financial News

Microbiome company A-Mansia secures €16M

A-Mansia Biotech S.A. (Louvain-la-Neuve, Belgium) raised €13 million ($16 million) in the first close of a tranched series A round led by Seventure Partners with participation from Fonds Vives II, the SRIW Life Sciences, Nivelinvest...
16:03 , Apr 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Chikungunya virus; Zika virus Mouse studies suggest a vaccinia virus-based vaccine expressing Zika and Chikungunya viral antigens could help prevent Zika and Chikungunya infections. The vaccine consists of seven viral antigens encoded by an...
04:15 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...